Navigation Links
ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute

RANCHO CORDOVA, Calif., Nov. 4, 2010 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. (Nasdaq: KOOL), a leading supplier of innovative products and services that process and store adult stem cells, said today that revenues for the first quarter of fiscal 2011 were $7.0 million, a 35 percent increase over revenues of $5.2 million in the first quarter of fiscal 2010.

In a separate release today, the Company announced it has signed a comprehensive distribution agreement with Nanshan Memorial Medical Institute (Nanshan), a progressive regenerative medicine company covering China and Hong Kong.  Nanshan distributes medical products and has operated multiple, large healthcare facilities including hospitals, stem cell banks and research centers.

The Company also announced it has retained an investment banker for strategic advisory purposes to facilitate potential top line growth and the identification and evaluation of potential business and product acquisitions.

First Quarter ResultsThe Company recorded disposable revenues of $4.4 million in the first quarter of fiscal 2011 versus disposable revenues of $3.0 million in the first quarter of fiscal 2010.

For the quarter ended September 30, 2010, the Company reported a net loss of $68,000, or $0.00 per share, compared to a net loss of $2.2 million, or $0.16 per share, in the first quarter a year ago. Included in the Company's results for the first quarter of fiscal 2011 were approximately $160,000 in severance and restructuring costs and an early termination fee related to a facility lease. The results for the first quarter of fiscal 2011 compare to a net loss of $171,000, or $0.01 per share, in the fourth quarter of fiscal 2010. The per share results for all periods have been adjusted to reflect the impact of the Company's reverse stock split that occurred at the close of business on August 26, 2010.  The Company ended the first quarter of fiscal 2011 with $10.2 million in cash versus $10.7 million in cash at the end of fiscal 2010.

"For the fifth consecutive quarter, we have improved our bottom line performance.  We reduced our net loss by $2.1 million in the first quarter of fiscal 2011 compared to the first quarter of fiscal 2010. Absent the severance, restructuring and lease termination charges, we would have achieved a profitable quarter," said J. Melville Engle, Chairman and Chief Executive Officer.

"Our year-over-year revenue growth was driven by a 73 percent increase in AXP® AutoXpress™ (AXP) System bag set revenues.  However, it should be noted that AXP disposable sales were higher than the prior year same quarter by $1.2 million, due primarily to GE Healthcare (GEHC) increasing their inventory levels approximately $1.0 million to meet certain customer requirements.  We do not expect these inventory accumulations to continue into next quarter.  Without the inventory build, total sales would have been approximately $6.0 million, an increase of 15 percent versus a year ago," he said.

The Company also said it filed an updated 510(k) submission seeking market clearance from the FDA for the use of its Res-Q technology in the preparation of platelet rich plasma (PRP) from peripheral blood. In mid-October, ThermoGenesis announced a PRP cardiovascular license and distribution agreement for Res-Q with BioParadox, Inc., a newly-formed regenerative medicine company focusing on point-of-care cardiovascular therapies.

"The agreement with BioParadox places us squarely in the emerging field of PRP and is an important milestone in our initiative to create novel applications for our proprietary Res-Q technology," Engle said.

Company Awarded Federal Grant The Company also announced today that, on October 29th, it was awarded $244,000 in federal grant funding from the Department of Health and Human Services through the Patient Protection and Affordable Care Act. Grants were available for up to 50 percent of expenses directly related to qualifying products or therapies designed to treat or prevent diseases or other chronic conditions.  The award was for the development and commercialization of the Company's Res-Q platform technology.

"We are very excited to have been awarded this grant as it is an important validation of our Res-Q technology as an effective platform for the delivery of life-saving therapeutics by the department of Health and Human Services. These funds will further our product portfolio expansion efforts," said Engle.

Investment Banking Strategic Advisors The Company also said it has engaged an investment bank for strategic advisory services to evaluate opportunities to accelerate its business development reach and activities.  "We are excited about the potential in the regenerative medicine market and believe there may be incremental growth prospects beyond those organic to our business.  Our strategic direction includes partnering, expansion of our product offerings and additional geographic reach," said Matthew T. Plavan, Chief Financial Officer and Head of Business Development.

With respect to the financial outlook for the remainder of fiscal 2011, the Company expects to experience a double-digit sales increase year-over year with growth in both its cord blood and bone marrow business lines. The Company also expects steady improvement in gross margins and continued leverage of its operating expenses. Excluding costs associated with the engagement of an investment banker, the Company expects to be profitable on a quarterly basis and for the year.

Engle Named ChairmanSeparately, Engle was named Chairman of the Board and Chief Executive Officer at the firm's October board meeting, replacing Hubert (Huck) Huckel, MD, who became Chairman, Emeritus. "We would like to thank Huck for his excellent stewardship and many contributions as Board Chairman over the last few years.  We are pleased with Mel's demonstrated leadership and business acumen and are delighted to be passing the baton to him as the new Chairman," said Patrick J. McEnany, ThermoGenesis' lead independent director.

Company's Conference Call and WebcastManagement will host a conference call today at 2:00 PM Pacific (5 PM Eastern) to review the fiscal 2011 first quarter results.Conference call details:Dial-in (U.S.):

1-800-860-2442Dial-in (International):

1-412-858-4600Conference Name:

"ThermoGenesis"To listen to the audio webcast of the call during or after the event, please visit

An audio replay of the conference call will be available beginning approximately two hours after completion of the call for the following five business days

To access the replay:Access number (U.S.):

1-877-344-7529Access number (Internationally):

1-412-317-0088Conference ID#:

385107About ThermoGenesis Corp.ThermoGenesis Corp. ( is a leader in developing and manufacturing automated blood processing systems and disposable products that enable the manufacture, preservation and delivery of cell and tissue therapy products. These include:

  • The BioArchive® System, an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries for cryopreserving and archiving cord blood stem cell units for transplant.
  • AXP® AutoXpress™ Platform (AXP), a proprietary family of automated devices that includes the AXP and the MXP™ MarrowXpress™ and companion sterile blood processing disposables for harvesting stem cells in closed systems. The AXP device is used for the processing of cord blood. The MXP is used for the preparation of cell concentrates, including stem cells, from bone marrow aspirates in the laboratory setting.
  • The Res-Q™ 60 BMC (Res-Q), a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates.
  • The CryoSeal® FS System, an automated device and companion sterile blood processing disposable, used to prepare fibrin sealants from plasma in about an hour. The CryoSeal FS System is approved in the U.S. for liver resection surgeries. The CryoSeal FS System has received the CE-Mark which allows sales of the product throughout the European community.

  • This press release contains forward-looking statements.  These statements involve risks and uncertainties that could cause actual outcomes to differ materially from those contemplated by the forward-looking statements. Several factors including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortages, production delays, changes in the markets for customers' products, introduction timing and acceptance of our new products scheduled for fiscal year 2011, and introduction of competitive products and other factors beyond our control could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2011.  A more complete description of these and other risks that could cause actual events to differ from the outcomes predicted by our forward-looking statements is set forth under the caption "Risk Factors" in our annual report on Form 10-K and other reports we file with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.

    ThermoGenesis Corp.Web site: http://www.thermogenesis.comContact: Investor Relations+1-916-858-5107, orir@thermogenesis.comFinancialsThermoGenesis Corp.Condensed Consolidated Balance Sheets (Unaudited)September 30,

    2010June 30,

    2010ASSETSCurrent assets: Cash and cash equivalents$10,193,000 $10,731,000  Accounts receivable, net6,449,000 6,095,000 Inventories5,065,000 5,034,000  Prepaid expenses and other current assets300,000 301,000 Total current assets22,007,000 22,161,000 Equipment, net1,591,000 1,701,000 Other assets147,000 168,000 $23,745,000 $24,030,000 Current liabilities: Accounts payable$2,409,000 $2,383,000  Other current liabilities2,751,000 3,191,000 Total current liabilities5,160,000 5,574,000 Long-term liabilities692,000 677,000 Stockholders' equity17,893,000 17,779,000 $23,745,000 $24,030,000 ThermoGenesis Corp.Condensed Consolidated Statements of Operations (Unaudited)Three Months Ended
    September 30,20102009Net revenues$6,997,000$5,193,000Cost of revenues4,402,0003,636,000Gross profit2,595,0001,557,000Expenses:Selling, general and administrative1,940,0002,163,000Research and development725,0001,594,000Total operating expenses2,665,0003,757,000Interest and other income, net2,00011,000Net loss($68,000)($2,189,000)Per share data:Basic and diluted net loss per common share($0.00)($0.16)Shares used in computing per share data14,023,27114,023,240ThermoGenesis Corp.Condensed Consolidated St
    atements of Cash Flows (Unaudited)Three Months Ended,

    September 30,20102009Cash flows from operating activities:Net loss

    ($68,000)($2,189,000)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization

    128,000111,000Stock based compensation expense

    182,000162,000Loss on impairment of equipment

    --26,000Accretion of discount on short-term investments

    --(1,000)Net change in operating assets and liabilities:Accounts receivable, net


    (31,000)(57,000)Prepaid expenses and other current assets

    1,000259,000Other assets

    21,0002,000Accounts payable

    26,000(214,000)Accrued payroll and related expenses

    81,000(209,000)Deferred revenue

    (376,000)(154,000)Other liabilities

    (129,000)237,000Net cash used in operating activities

    (519,000)(2,255,000)Cash flows from investing activities:Capital expenditures

    (18,000)(256,000)Purchase of investments

    --(1,499,000)Maturities of investments

    --99,000Net cash used in investing activities

    (18,000)(1,656,000)Cash flows from financing activities:Payments on capital lease obligations

    (1,000)(1,000)Net cash used in financing activities

    (1,000)(1,000)Net (decrease) increase in cash and cash equivalents

    (538,000)(3,912,000)Cash and cash equivalents at beginning of period

    10,731,0006,655,000Cash and cash equivalents at end of period


    SOURCE ThermoGenesis Corp.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. ThermoGenesis Corp. to Announce First Quarter Fiscal 2011 Results on November 4, 2010
    2. ThermoGenesis Announces Platelet Rich Plasma (PRP) Res-Q Cardiovascular Licensing Agreement
    3. ThermoGenesis Announces Fourth Quarter Revenues of $7.2 Million; Reduces Net Loss to $171,000
    4. ThermoGenesis Regains Compliance With NASDAQ Listing Rules
    5. ThermoGenesis Announces Reverse Stock Split Effective on NASDAQ Capital Market August 27, 2010
    6. ThermoGenesis Announces Agreement for Adipose Tissue Clinical Program
    7. ThermoGenesis Names Jorge Artiles Vice President, Chief Quality and Regulatory Affairs Officer
    8. ThermoGenesis Announces National Institute of Health Grant
    9. ThermoGenesis Announces MXP Involvement in New Regenerative Medicine Initiatives
    10. IRIDEX Reports Improved Third Quarter 2010 Financial Results
    11. Genoptix Reports Operating Results for the Third Quarter and First Nine Months of 2010
    Post Your Comments:
    (Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
    (Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
    (Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian ... On The Brink” is the creation of published author, William Nowers. Captain Nowers ... a WWII veteran, he spent thirty years in the Navy. Following his career ...
    (Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
    (Date:10/12/2017)... ... October 12, 2017 , ... ... that we intend to develop to enable prevention of a major side effect ... hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed ...
    (Date:10/12/2017)... Wesley Chapel, FL (PRWEB) , ... October 12, 2017 , ... ... Chapel is holding a treadmill relay – Miles by Moonlight to raise money for ... by donating $300 or more. , Teams will work together to keep their ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer Dr. ... colleagues, skilled nursing facility medical directors and other clinicians at various events in ... , "At many of these conferences we get to educate other physicians, facility ...
    Breaking Medicine News(10 mins):